Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.
In the present study we tested the phenotypic profile as well as several immunological responses of peripheral blood mononuclear cells (PBMC) isolated from melanoma patients. These patients underwent chemotherapy with dacarbazine and carboplatin from day 1 to day 22, followed by immunotherapy of low-dose recombinant interleukin-2 and recombinant interferon alpha administered subcutaneously from day 36 to day 75. The PBMC from 14 patients were isolated on day 0 before chemotherapy, on day 36 after chemotherapy and on day 76 after immunotherapy. After chemotherapy, a decrease in CD16+ cells and increase in CD3+ and CD4+ cells correlated with a significant decrease in the generation of lymphokine-activated killer (LAK) activity. After immunotherapy, an increase in CD16+ cells correlated with an increase in the induction of LAK activity. A comparison between responding and non-responding patients revealed statistically significant differences in LAK activity of PBMC and response to concanavalin A following chemotherapy, and in the percentage of CD8+ cells following immunotherapy. Our results point toward the value of continuing such a study on a larger population of cancer patients in order to select the appropriate bioassays for monitoring and predicting the clinical responsiveness to combined therapies.
Eisenthal
A
A
Department of Oncology, Tel-Aviv Sourasky Medical Center, Israel.
Skornick
Y
Y
Ron
I
I
Zakuth
V
V
Chaitchik
S
S
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002455:Cell Division / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D003208:Concanavalin A; D003606:Dacarbazine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy; D007370:Interferon Type I / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects* / Q000276:immunology*; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000188:drug therapy / Q000628:therapy; D008875:Middle Aged; D010835:Phytohemagglutinins; D011043:Pokeweed Mitogens; D011994:Recombinant Proteins
D015703:Antigens, CD; D007370:Interferon Type I; D007376:Interleukin-2; D010835:Phytohemagglutinins; D011043:Pokeweed Mitogens; D011994:Recombinant Proteins; D003208:Concanavalin A; D003606:Dacarbazine; D016190:Carboplatin